Table 1. Clinical characteristics of patients in mortality and non-mortality groups in training set and testing set

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | Training Set (n=5488) | | Testing Set (n=2322) | |
|  |  | Mortality  (n=97) | non-mortality  (n=5391) | mortality  (n=40) | non-mortality (n=2282) |
| Age | Median (IQR) | 84 (76,88) | 67 (60,75) | 82.5 (77,90) | 67 (59,75) |
| Gender | Female | 21 (21.65%) | 1378 (25.56%) | 10 (25%) | 627 (27.48%) |
|  | Male | 76 (78.35%) | 4013 (74.44%) | 30 (75%) | 1655 (72.52%) |
| D-Dimer | Median (IQR) | 2.41 (1.26,4.29) | 0.33 (0.18,0.7) | 3.975 (1.17,7.69) | 0.34 (0.19,0.69) |
| cTnI | Median (IQR) | 1.469 (0.303,9.426) | 0.071 (0.011,0.466) | 2.582 (0.407,12.846) | 0.067 (0.01,0.419) |
| CK | Median (IQR) | 198 (70,707) | 82 (57.5,129) | 144 (59,715) | 85 (58,135) |
| NT-proBNP | Median (IQR) | 11034.5 (5336.5,31336.5) | 232 (74.7,816.9) | 7227.5 (2053.5,22224.5) | 239.6 (72.8,830) |
| LDH | Median (IQR) | 487.5 (282,764) | 179 (153.4,224.6) | 477.5 (271,955) | 180 (153,231) |
| HDL cholesterol | Median (IQR) | 0.63 (0.36,0.91) | 0.99 (0.83,1.18) | 0.8 (0.56,1.06) | 0.99 (0.82,1.2) |
| LDL cholesterol | Median (IQR) | 1.41 (1,2.25) | 2.38 (1.81,3.1) | 1.94 (1.24,2.69) | 2.38 (1.8,3.15) |
| Total cholesterol | Median (IQR) | 2.83 (2.11,3.67) | 3.85 (3.19,4.63) | 3.39 (2.67,3.98) | 3.83 (3.19,4.66) |
| Triglycerides | Median (IQR) | 1.37 (0.88,1.99) | 1.35 (1,1.91) | 1.29 (1.06,3.25) | 1.35 (1.01,1.87) |
| Hypertension | No | 20 (20.62%) | 1590 (29.49%) | 11 (27.5%) | 670 (29.36%) |
|  | Yes | 77 (79.38%) | 3801 (70.51%) | 29 (72.5%) | 1612 (70.64%) |
| Diabetes | No | 57 (58.76%) | 3474 (64.44%) | 24 (60%) | 1470 (64.42%) |
|  | Yes | 40 (41.24%) | 1917 (35.56%) | 16 (40%) | 812 (35.58%) |
| Clopidogrel | No | 28 (28.87%) | 786 (14.58%) | 13 (32.5%) | 325 (14.24%) |
|  | Yes | 69 (71.13%) | 4605 (85.42%) | 27 (67.5%) | 1957 (85.76%) |
| Beta-blockers | No | 62 (63.92%) | 1357 (25.17%) | 26 (65%) | 589 (25.81%) |
|  | Yes | 35 (36.08%) | 4034 (74.83%) | 14 (35%) | 1693 (74.19%) |
| Calcium channel blockers | No | 74 (76.29%) | 3460 (64.18%) | 28 (70%) | 1433 (62.8%) |
|  | Yes | 23 (23.71%) | 1931 (35.82%) | 12 (30%) | 849 (37.2%) |
| Statins | No | 16 (16.49%) | 193 (3.58%) | 8 (20%) | 89 (3.9%) |
|  | Yes | 81 (83.51%) | 5198 (96.42%) | 32 (80%) | 2193 (96.1%) |
| Low molecular weight heparin | No | 42 (43.3%) | 2103 (39.01%) | 12 (30%) | 943 (41.32%) |
|  | Yes | 55 (56.7%) | 3288 (60.99%) | 28 (70%) | 1339 (58.68%) |
| Ticagrelor | No | 88 (90.72%) | 4253 (78.89%) | 38 (95%) | 1819 (79.71%) |
|  | Yes | 9 (9.28%) | 1138 (21.11%) | 2 (5%) | 463 (20.29%) |
| Glycoprotein IIb/IIIa receptor antagonist | No | 92 (94.85%) | 4600 (85.33%) | 36 (90%) | 1953 (85.58%) |
|  | Yes | 5 (5.15%) | 791 (14.67%) | 4 (10%) | 329 (14.42%) |
| Angiotensin receptor antagonist | No | 85 (87.63%) | 3713 (68.87%) | 30 (75%) | 1537 (67.35%) |
|  | Yes | 12 (12.37%) | 1678 (31.13%) | 10 (25%) | 745 (32.65%) |
| ACEI | No | 73 (75.26%) | 2544 (47.19%) | 28 (70%) | 1065 (46.67%) |
|  | Yes | 24 (24.74%) | 2847 (52.81%) | 12 (30%) | 1217 (53.33%) |
| Aspirin | No | 44 (45.36%) | 568 (10.54%) | 21 (52.5%) | 254 (11.13%) |
|  | Yes | 53 (54.64%) | 4823 (89.46%) | 19 (47.5%) | 2028 (88.87%) |
| PCI | No | 93 (95.88%) | 4890 (90.71%) | 37 (92.5%) | 2078 (91.06%) |
|  | Yes | 4 (4.12%) | 501 (9.29%) | 3 (7.5%) | 204 (8.94%) |
| Thrombolysis with drugs | No | 96 (98.97%) | 5388 (99.94%) | 40 (100%) | 2281 (99.96%) |
|  | Yes | 1 (1.03%) | 3 (0.06%) | 0 (0%) | 1 (0.04%) |

Note: cTnI: cardiac troponin I; CK: creatine kinase; NT-proBNP: N-terminal pro-B-type natriuretic peptide; LDH: lactate dehydrogenase; HDL cholesterol: high-density lipoprotein cholesterol; LDL cholesterol: low-density lipoprotein cholesterol; ACEI: angiotensin converting enzyme inhibitor; PCI: percutaneous coronary intervention